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Abstract
Identifying the signalling pathways underlying the pathophysiology of schizophrenia is an essential step
in the rational development of new antipsychotic drugs for this devastating disease. Evidence from
genetic, transgenic and post-mortem studies have strongly supported neuregulin-1 (NRG1)-ErbB4
signalling as a schizophrenia susceptibility pathway. NRG1-ErbB4 signalling plays crucial roles in
regulating neurodevelopment and neurotransmission, with implications for the pathophysiology of
schizophrenia. Post-mortem studies have demonstrated altered NRG1-ErbB4 signalling in the brain of
schizophrenia patients. Antipsychotic drugs have different effects on NRG1-ErbB4 signalling depending
on treatment duration. Abnormal behaviours relevant to certain features of schizophrenia are displayed in
NRG1/ErbB4 knockout mice or those with NRG1/ErbB4 over-expression, some of these abnormalities can
be improved by antipsychotic treatment. NRG1-ErbB4 signalling has extensive interactions with the
GABAergic, glutamatergic and dopaminergic neurotransmission systems that are involved in the
pathophysiology of schizophrenia. These interactions provide a number of targets for the development of
new antipsychotic drugs. Furthermore, the key interaction points between NRG1-ErbB4 signalling and
other schizophrenia susceptibility genes may also potentially provide specific targets for new
antipsychotic drugs. In general, identification of these targets in NRG1-ErbB4 signalling and interacting
pathways will provide unique opportunities for the development of new generation antipsychotics with
specific efficacy and fewer side effects.
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Abstract
Objectives: Identifying the signalling pathways underlying the pathophysiology of
schizophrenia is an essential step in the rational development of new antipsychotic
drugs for this devastating disease. Evidence from genetic, transgenic and postmortem studies have strongly supported neuregulin-1 (NRG1)–ErbB4 signalling as a
schizophrenia susceptibility pathway. NRG1–ErbB4 signalling plays crucial roles in
regulating neurodevelopment and neurotransmission, with implications for the
pathophysiology of schizophrenia. Postmortem studies have demonstrated altered
NRG1–ErbB4 signalling in the brain of schizophrenia patients. Antipsychotic drugs
have different effects on NRG1–ErbB4 signalling depending on treatment duration.
Abnormal behaviours relevant to certain features of schizophrenia are displayed in
NRG1/ErbB4 knockout mice or those with NRG1/ErbB4 over-expression, some of
these abnormalities can be improved by antipsychotic treatment. NRG1–ErbB4
signalling has extensive interactions with the GABAergic, glutamatergic and
dopaminergic neurotransmission systems that are involved in the pathophysiology of
schizophrenia. These interactions provide a number of targets for the development of
new antipsychotic drugs. Furthermore, the key interaction points between NRG1–
ErbB4 signalling and other schizophrenia susceptibility genes may also potentially
provide specific targets for new antipsychotic drugs. In general, identification of these
targets in NRG1–ErbB4 signalling and interacting pathways will provide unique
opportunities for the development of new generation antipsychotics with specific
efficacy and fewer side effects.

1. INTRODUCTION
Schizophrenia is a devastating psychiatric disorder, affecting 1% of the population
worldwide, and ranks among the top ten causes of disability in developed countries
(Murray and Lopez 1996). Schizophrenia is clinically characterised by positive
symptoms (such as hallucinations and delusions), negative symptoms (such as flat or
blunted affect, poverty of speech, and social withdrawal), and cognitive deficits (such
as memory deficits, attenuated attention processes, and executive functioning
impairment) (Austin 2005). Currently, the symptoms of schizophrenia are principally
controlled by pharmacological treatment, i.e., antipsychotic medications that are
primarily effective for positive symptoms (Leucht et al. 2009; Vohora 2007).
However, current antipsychotics have limited efficacy for negative symptoms and
cognitive deficits, and have some severe side effects (Deng et al. 2010; Vohora 2007).
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Over the past half century, the discovery and development of antipsychotic drugs
were largely dependent on the serendipitous observation of the clinical effects of
some compounds, studies on the underlying mechanisms of drug actions, and
modifications of previously used drugs for improving efficacy and reducing side
effects (Lewis and Gonzalez-Burgos 2006). Unfortunately, these approaches are
largely not derived from an understanding of the disease pathophysiology, particularly
the aetiology-based molecular pathways of schizophrenia. Although the aetiology and
pathophysiology of schizophre nia are still not fully understood, evidence from
genetic, post-mortem and animal studies over the past decade have identified a
number of susceptibility genes and related pathways for schizophrenia, including
neuregulin-1 (NRG1), ErbB4 receptor, disrupted-in-schizophrenia-1 (DISC1),
dysbindin-1, catechol-O-methyl transferase (COMT), and Akt (Jaaro-Peled et al. 2009;
Karam et al. 2010; Lang et al. 2007). A key question is whether these susceptibility
genes and their related pathways have therapeutic potential for the treatment of
schizophrenia. Recent evidence suggests that the NRG1–ErbB4 signalling pathway
could be a potential target for the development of new generation antipsychotic drugs
(Hahn 2011; Karam et al. 2010).
The NRG1–ErbB4 signalling pathway is involved in multiple biological functions in
neurodevelopment, including neuronal migration, glial cell development, axon
myelination and guidance, dendritic development, and neurotransmitter signalling that
have been implicated in schizophrenia (Buonanno 2010; Geddes et al. 2011; Mei and
Xiong 2008; Rico and Marin 2011). In fact, the NRG1 and ErbB4 genes have been
identified as candidate genes for schizophrenia by many association studies in several
ethnic groups (Law et al. 2007; Li et al. 2006; Liu et al. 2005; Lu et al. 2010;
Nicodemus et al. 2010; Petryshen et al. 2005; Shiota et al. 2008; Squassina et al. 2010;
Stefansson et al. 2003; Williams et al. 2003; Yang et al. 2003); although there are also
some contradictory reports (Garcia-Barcelo et al. 2011; Ikeda et al. 2008; Ingason et
al. 2006; Jonsson et al. 2009). The studies in both post-mortem brain tissue and blood
lymphocytes report altered expression of NRG1 and ErbB4, and their signalling
activity in schizophrenic patients (Chong et al. 2008; Hahn et al. 2006; Law et al.
2006; Pan et al. 2011). Studies in transgenic animal models showed that impaired
NRG1–ErbB4 signalling leads to behavioural abnormalities relevant to certain
features of schizophrenia and that these behavioural deficits could be improved by
anti psychotic treatment (Barros et al. 2009; Dejaegere et al. 2008; Kato et al. 2010;
Pan et al. 2011; Rimer et al. 2005; Savonenko et al. 2008; Stefansson et al. 2002).
Accumulated evidence shows that aberrant NRG1–ErbB4 signalling may contribute
to schizophrenia symptoms, particularly positive and cognitive symptoms (Hall et al.
2006; Kang et al. 2012; Roussos et al. 2011; Shamir et al. 2012; Yokley et al. 2012);
however, they contribute less to negative symptoms (Rethelyi et al. 2010). In addition,
various antipsychotics have different effects on NRG1 and ErbB4 expression and
signalling (Pan et al 2011). Accumulated evidence shows that NRG1–ErbB4
signalling is closely interacted with several neurotransmitter pathways (glutamatergic,
GABAergic and dopaminergic pathways) that are crucial in the pathophysiology of
schizo phrenia and antipsychotic drug efficacy (Buonanno 2010; Lewis and
Moghaddam 2006; Neddens et al. 2011; Pitcher et al. 2011). Therefore, NRG1–ErbB4
signalling may provide some important targets for schizophrenia treatment. This
article will review the evidence regarding the effects of antipsychotics on alterations
in NRG1–ErbB4 function, and provide insight into the potential of the NRG1–ErbB4
signalling pathway as a novel target for the discovery of new antipsychotic drugs.
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2. NRG1ERBB4 SIGNALLING AND ITS INVOLVEMENT IN THE
PATHOPHYSIOLOGY OF SCHIZOPHRENIA
2.1
The structures of NRG1 proteins and the downstream signalling
pathways
NRG1 is among a family of growth and differentiation factors encoded by four
individual genes (NRG1-4). The NRG1 gene generates at least 31 isoforms in humans,
presumably due to multiple promoters and alternative splicing, that can be grouped
into six types of proteins with different structures and distinct functional properties.
Most NRG1 isoforms possess an EGF-like domain, located in the membraneproximal area of the extracellular part. There are two types of EGF-like domain: αtype EGF-like domain and β-type EGF-like domain. In the NRG1 types I, II, IV and
V isoforms, an immunoglobulin (Ig)-like domain connects with the N-terminal
sequence and the EGF-like domain. However, the type III isoforms contain a
cysteine-rich domain (CRD) that has an additional transmembrane domain (TMN).
The N-terminal sequence of NRG1 types III and VI is connected directly to the EGFlike domain. The EGF-like domain is connected with a C-terminal cytoplasmic tail
(for review, see Mei and Xiong 2008). Most NRG1 proteins are generated by
proteolytic processing (ectodomain shedding) of membrane-anchored precursors (proNRG1s) at the membrane-proximal region that lies on the C-terminal side of the
extracellular part, which is regulated by three type I transmembrane proteases: tumor
necrosis factor-α converting enzyme (TACE, also known as ADAM17) (Montero et al.
2007), β-site of amyloid precursor protein cleaving enzyme (BACE, also known as
memapsin 2) (Hu et al. 2006; Willem et al. 2006) and meltrin β (also known as
ADAM19) (Wakatsuki et al. 2004; Yokozeki et al. 2007). Eventually diffusible,
mature NRG1 proteins are released into the extracellular space (except in the case of
NRG1 type III) (Falls 2003). The remaining intracellular membrane-bound NRG1
fragment can be cleaved by Aph1B/C-γ-secretase, generating an intracellular domain
that can relocate into the nucleus and regulate gene transcription (Bao et al. 2003).
Diffusible NRG1 binds with a family of type I transmembrane receptor tyrosine
kinases called ErbB proteins, including ErbB2, ErbB3 and ErbB4 (Bublil and Yarden
2007). The ErbB protein family consists of four members that are EGF receptors
(EGFR), known as ErbB1, ErbB2, ErbB3 and ErbB4. Upon the stimulation of NRG1,
ErbB proteins are dimerised to form several types of homodimers (e.g., ErbB4–ErbB4)
and heterodimers (e.g., ErbB2–ErbB3, ErbB2–ErbB4 and ErbB4-EGFR) (Falls 2003;
Mei and Xiong 2008). NRG1 does not bind to ErbB1 and ErbB2. EGFR, encoded by
the ERBB1 gene, cannot bind to NRG1, but forms an activated heterodimer with
ErbB4. ErbB2, encoded by the ERBB2 gene, also functions as a coreceptor by
forming heterodimers with ligand-bound ErbBs (Falls 2003; Mei and Xiong 2008).
The other two ErbB proteins, ErbB3 and ErbB4, can bind to NRG1, in which ErbB4
homodimers can both interact with NRG1 and become activated by it as a tyrosine
kinase (Falls 2003; Mei and Xiong 2008). On the other hand, although ErbB3 has
been previously considered as kinase-inactive (Falls 2003; Yarden and Sliwkowski
2001), a recent report showed that the ErbB3 kinase domain is competent to bind ATP
and catalyse autophosphorylation (Shi et al. 2010). Compared to ErbB3 homodimers
(inactive) or ErbB4 homodimers that signal only weakly, ErbB3/ErbB2 and
ErbB4/ErbB2 heterodimers contribute to prolonged and enhanced downstream
signalling (Yarden and Sliwkowski 2001). The ErbB3 and ErbB4 protein are encoded
by the ERBB3 and ERBB4 genes, among them ERBB4 gene has been considered as a
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susceptibility gene for schizophrenia (Garcia et al. 2000; Law et al. 2007; Nicodemus
et al. 2006; Shiota et al. 2008; Silberberg et al. 2006). Although the ERBB3 gene has
also been considered as a potential schizophrenia candidate gene (Li et al. 2009a), the
association of the ERBB3 gene with schizophrenia has not been confirmed in several
studies (Kanazawa et al. 2007; Li et al. 2009b). Therefore, this review will focus on
NRG1 signalling through the ErbB4 receptor. An ErbB4 protein contains two
extracellular CRDs, a TMN, an intracellular juxtamembrane (JM) region, a tyrosine
kinase domain and a C-terminal cytoplasmic tail (CYT) (Mei and Xiong 2008).
NRG1s with the β-type EGF-like domain have a higher affinity to ErbB receptors
(especially the ErbB4 receptor) than NRG1s with the α-type EFG-like domain (Jones
et al. 1999; Tzahar et al. 1994; Wen et al. 1994) and promotes the phosphorylation of
ErbB receptors 10 times more effectively than NRG1α (Pinkas-Kramarski et al. 1996).
In addition, a report by Falls (2003) stated that NRG1β isoforms are 10–100 times
more potent than NRG1α isoforms, and that NRG1α is mostly involved in breast
development. Therefore, NRG1β isoforms are more likely to be associated with the
pathophysiology of schizophrenia than NRG1α isoforms. NRG1 stimulus leads to
dimerisation and kinase activation of the ErbB4 receptor, resulting in autoand transphosphorylation of the intracellular domains, which activates several signalling
pathways. For example, NRG1-induced stimulation of ErbB4 receptor frequently
activates the PI3K (phosphatidyl inositol-3-kinase)– Akt–S6K pathway. ErbB4 CYT1 contains a PI3K-binding site that binds the p85 subunit of PI3K and activates this
kinase, which in turn phosphorylates and activates downstream Akt and S6K (Mei
and Xiong 2008). The PI3K–Akt–S6K pathway mediates NRG1-induced cell survival,
and neuronal and synaptic development (Junttila et al. 2000; Kainulainen et al. 2000;
Krivosheya et al. 2008). By acting through the ErbB4-EGFR heterodimer, NRG1 can
activate Src family kinases, PLCγ, c-Abl and JNK. Furthermore, NRG1 also activates
the Raf-MAPK (mitogen activate protein kinase) pathway (Mei and Xiong 2008).
2.2
Pathological alterations of NRG1ErbB4 signalling in schizophrenia
patients
Both post-mortem studies and behavioural studies in animal models have suggested
abnormalities of the NRG1–ErbB4 pathway in schizophrenia (Pan et al. 2011).
Several postmortem studies have found an increase in the mRNA expression of NRG1
type I in the prefrontal cortex (PFC) (Hashimoto et al. 2004) and the hippocampus
(Law et al. 2006); moreover, an increase of the protein level of the NRG1 intracellular
part in the PFC has also been reported (Chong et al. 2008). However, Hashimoto et al.
(2004) have shown a decrease in the ratios of type II/I and type II/III mRNA
expressions (i.e., a relatively decreased expression of NRG1 type II) (Hashimoto et al.
2004). A study in elderly individuals with schizophrenia has indicated an increased
NRG1 type II expression but decreased NRG1 type I expression in the PFC
(Brodmann area [BA] 10) (Parlapani et al. 2010). Additionally, Bertram and
colleagues (2007) have found using immunohistochemistry and Western blot analysis
that the NRG1α isoform is decreased in the white and grey matter of the PFC
(Bertram et al. 2007). Barakat et al. (2010) reported that the full-length type III NRG1
precursor did not differ between individuals with schizophrenia and healthy controls,
but the levels of NRG1 type III C-terminal fragment significantly decreased in the
BA6 of schizophrenia patients (Barakat et al. 2010). Abnormal expression of NRG1
has also been reported in the periphery, although the results were not consistent. For
example, the expression levels of NRG1 transcript variants in type I and type III
isoforms were significantly increased in peripheral blood lymphocytes (PBLs) in
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schizophrenia (Petryshen et al. 2005), whereas a decrease in NRG1 mRNA expression
in PBLs and serum NRG1 immunoreactivity were reported by other studies (Shibuya
et al. 2010; Zhang et al. 2008, 2011). Decreased peripheral NRG1 mRNA in PBLs has
been found in high-risk individuals who later developed psychosis (Kiss et al. 2012).
However, a recent study reported no difference in expression of NRG1 mRNA in
immortalized lymphocytes between schizophrenia and control subjects (Yamamori et
al. 2011). It is worth noting that treatment with the antipsychotics risperidone and
quetiapine has been reported to increase NRG1 mRNA expression in PBLs in firstonset schizophrenia patients (Zhang et al. 2008, 2011).
ErbB4 receptor expression has also been shown to be abnormal in post-mortem brain
studies. Increases in the protein expression of both the full-length ErbB4 receptor and
the isoforms containing CYT-1 domain have been reported in the PFC of
schizophrenia patients (Chong et al. 2008; Silberberg et al. 2006). In addition, the
mRNA expression of isoforms containing CYT-1 domain and a JM-a domain was
also increased in the dorsal PFC of schizophrenia patients (Law et al. 2007). Hahn et
al. (2006) found that, although the expression of both NRG1 and ErbB4 receptors was
not significantly changed in the PFC of schizophrenia subjects, a marked increase in
NRG1-induced activation of the ErbB4 receptor and activity of its downstream
signalling components were observed in patients with schizophrenia (Hahn et al.
2006). Although the results are not completely consistent, the majority of studies
demonstrate elevated NRG1–ErbB4 signalling in the brain of individuals with
schizophrenia (Pan et al. 2011). Furthermore, whether there are developmental
differences in NRG1–ErbB4 signalling in patients with psychotic symptoms has not
been investigated.
In brief, while not completely consistent, current data from studies in post-mortem
brain tissue and PBLs have demonstrated altered NRG1–ErbB4 signalling in
schizophrenia. It is worth noting that there are a number of limitations to these studies.
Firstly, many reports focused on relative mRNA levels without attempting to address
the possible biological significance of the observed difference. For example, what
might be the biological relevance of the minor changes in the expression of NRG1
type I and ErbB4 reported previously (Chong et al. 2008; Hashimoto et al.2004)?
How might isoform-specific changes in expression affect function that could lead to
pathophysiological changes associated with schizophrenia? Recently, Liu et al. (2011)
reported the expression of specific NRG1 isoforms in the human and rat post-mortem
brain with quantitative data in copies/μg total RNA in addition to normalization of
mRNA levels to β-actin (Liu et al. 2011). This provides an important way to further
quantitatively analyse of specific NRG1 isoform expression as well as to compare
relative ratios to housekeeping genes in schizophrenia postmortem studies. In addition,
there are also problems in specificity of antibodies against specific NRG1 isoforms
and ErbB4 receptors in terms of interpretation of protein expression in post-mortem
tissue (Bare et al. 2011; Fazzari et al. 2010; Vullhorst et al. 2009). Therefore, future
postmortem studies using better quality controlled reagents and quantitative measures
are required in order to interpret the results and reveal how NRG1–ErbB4 signalling
contributes to the pathophysiology of schizophrenia.
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2.3
Evidence from studies of transgenetic models with NRG1/ErbB4
knockout and overexpression relevant to schizophrenia
Along with the findings from post-mortem studies, animals with abnormal NRG1–
ErbB4 functioning display behavioural deficits that resemble the symptoms of
schizophrenia, including hyperactivity in the novel open-field test and the alternatingY maze (Barros et al. 2009; Chesworth et al. 2012; Duffy et al. 2008, 2010; Gerlai et
al. 2000; Karl et al. 2007; Kato et al. 2010; O'Tuathaigh et al. 2007; Rimer et al. 2005;
Stefansson et al. 2002; van den Buuse et al. 2009), deficits in prepulse inhibition (PPI)
level (Barros et al. 2009; Chen et al. 2008; Deakin et al. 2009; Dejaegere et al. 2008;
Hong et al. 2008; Kato et al. 2010; Savonenko et al. 2008; Stefansson et al. 2002; van
den Buuse et al. 2009), and lateral inhibition (Rimer et al. 2005), as well as impaired
social activity (Kato et al. 2010; O'Tuathaigh et al. 2007). These transgenic animal
models have targeted mutiple mutations in NRG1 genes and the proteolytic
processing and cleavage of NRG1 proteins, including mutation or deletion of the Iglike domain (Rimer et al. 2005), TMN domain (NrgTM) (Chesworth et al. 2012; Karl
et al. 2007; O'Tuathaigh et al. 2007; Stefansson et al. 2002), type I (Deakin et al. 2009)
and type III of NRG1 (Chen et al. 2008), Aph1B/C-γ-secretase (Dejaegere et al. 2008),
and BACE1 (Savonenko et al. 2008). It is worth noting that animals with either
reduced (O'Tuathaigh et al. 2010; van den Buuse et al. 2009) or excessive expression
(Deakin et al. 2009; Kato et al. 2010) of the NRG1 gene showed similar behavioural
deficits. Recently, a knock-out mouse model with ErbB4 ablation specifically in the
parvalbumin (PV)positive interneurones (PV-ErbB4−/−) was reported to exhibit
schizophrenia-relevant phenotypes similar to those observed in NRG1 or ErbB4-null
mutant mice (Chen et al. 2010a; Wen et al. 2010). Together, these studies support the
hypothesis that abnormal NRG1–ErbB4 signalling is a potential factor for the
behavioural phenotypes of schizophrenia. Moreover, in these models, behavioural
phenotypes induced by altered NRG1–ErbB4 signalling are different depending on
the mutant domains of proteins, age and gender of animals, and the biological context
of the dysregulation (Desbonnet et al. 2009). For example, male NrgTM mice
displayed stronger behavioural deficits than female mutants in decreased response to
the locomotor-activating effects of acute PCP treatment (O'Tuathaigh et al. 2010), in
social withdrawal-like effects of Δ9-tetrahydrocannabinol treatment (Long et al.
2010a,b), and in fear conditioning and recognition of a previously encountered object
(Chesworth et al. 2012; Duffy et al. 2010). Sex-specific phenotypic effects were also
observed in exploratory and habituation behaviours: female NrgTM mice showed an
increase in walkovers and shifting of cage bedding, while male mutants exhibited
reduced grooming (O'Tuathaigh et al. 2006, 2008). On the other hand, hypomorphic
type II NRG1 (NrgTn) male rats failed to habituate to an open field, while female
NrgTn rats exhibited reduced locomotor activity and enhanced habituation to a novel
environment; and only female NrgTn rats had impaired PPI (Taylor et al. 2011).
Therefore, these results imply that specific personalised treatment may be developed
according to the different biological status of patients, although it also implies that the
treatment may be ineffective for patients of certain genotypes, ages and genders.
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3. INTERACTIONS BETWEEN NRG1ERBB4 SIGNALLING AND
NEUROTRANMISSION: RELATING TO THE PATHOPHYSIOLOGY
OF SCHIZOPHRENIA
3.1
The role of NRG1ErbB4 signalling in neurodevelopment in relation
to schizophrenia
It has been largely accepted that schizophrenia arises as a consequence of abnormal
brain development (Fatemi and Folsom 2009; Jaaro-Peled et al. 2009). NRG1 and
ErbB4 are highly expressed in the developing brain (Buonanno 2010; Liu et al. 2011).
NRG1 transcripts in the brain are expressed at their highest during embryonic, fetal
and early postnatal periods, and expression decreases with age (Buonanno 2010).
Considerable evidence has indicated that NRG1–ErbB4 signalling plays critical roles
in developmental processes, such as radial glia formation and neuronal migration
(Anton et al. 1997; Rio et al. 1997; Yau et al. 2003), glial cell development, axon
myelination and axon ensheathment (Calaora et al. 2001; Canoll et al. 1996;
Michailov et al. 2004; Nave and Salzer 2006; Schmucker et al. 2003; Taveggia et al.
2005), axon guidance (Bermingham-McDonogh et al. 1996; Gerecke et al. 2004;
Lopez-Bendito et al. 2006; Rieff et al. 1999), and dendritic development (Chen et al.
2010b; Gerecke et al. 2004; Rieff and Corfas 2006). NRG1 also affects the
development of the dopaminergic system and GABAergic interneurones (Balu and
Coyle 2011; Fazzari et al. 2010; Rico and Marin 2011; Roy et al. 2007). For example,
peripheral NRG1 administration in neonatal mice activates midbrain ErbB4 receptors
and elevates the expression, phosphorylation and activity of tyrosine hydroxylase
(TH). This results increases in the level of dopamine and dopamine release, and
induces a persistent hyper-dopaminergic state and behavioural impairments in
prepulse inhibition, latent inhibition, social behaviours and hypersensitivity to
methamphetamine (Kato et al. 2011). NRG1–ErbB4 signalling is critical for the
development of inhibitory circuitries and the wiring of GABA-mediated circuits in the
postnatal cerebral cortex (Fazzari et al. 2010). Therefore, this evidence further
supports the involvement of impaired NRG1–ErbB4 signalling in the development of
schizophrenia.
3.2
Effects of NRG1ErbB4 signalling on synaptic plasticity and
neurotransmission in the adult brain in relation to schizophrenia
3.2.1 Interaction between NRG1ErbB4 signalling and dopaminergic
neurotransmission
Dopaminergic dysfunction is one of the most widely accepted neurochemical
hypotheses of schizophrenia. It postulates that excess dopaminergic transmission in
the mesolimbic and striatal regions, and dopaminergic deficits in prefrontal regions,
are responsible for the positive symptoms and negative symptoms of schizophrenia,
respectively (Lang et al. 2007). Similarly, Kwon et al. (2008) found that intracerebral
infusion of NRG1β into the hippocampus increased extracellular dopamine levels
(Kwon et al. 2008). Direct intracerebral infusion of NRG1β into the substantia nigra
(SN) evokes an almost immediate overflow of striatal dopamine (Yurek et al. 2004).
Since ErbB4 receptors are mainly expressed on the dopamine neurons in the SN, these
results suggested that NRG1 can directly modulate the activity of mesostriatal
dopaminergic neurons (Abe et al. 2009; Zheng et al. 2009). Carlsson et al. (2011)
found that dopamine levels increased in the SN and the striatum of adult mice after
systemic administration of NRG1β (Carlsson et al. 2011). Together, these studies
7

consistently demonstrate that promoted NRG1 signalling is capable of increasing TH
levels and dopamine release, enhancing dopaminergic neurotransmission.
3.2.2 Interactions between NRG1ErbB4 signalling and glutamatergic
neurotransmission
considerable amount of research has demonstrated that the ionotropic glutamate
receptor N-methyl-D-aspartate (NMDA) plays a critical role in the pathogenesis of
schizophrenia, and that hypofunction of NMDA receptors is a major mechanism
underlying the pathophysiology of schizophrenia (Kantrowitz and Javitt 2010; Lewis
and Gonzalez-Burgos 2006). NMDA receptors are composed of a heterometric
assembly of subunits (NR1, NR2 and NR3), where the NR2 subunit shares a common
anchoring protein in the post synaptic density (PSD) with the ErbB4 receptor (Chen et
al. 2006; Cousins et al. 2009; Geddes et al. 2011). Accumulated evidence supports
that NRG1–ErbB4 signalling is capable of regulating the function of the NMDA
receptor through the NR2/PSD/ErbB4 complex. For example, MK-801 binding is
decreased in the PFC of mice with NRG1 EGF-domain mutation, implying reduced
expression of NMDA receptors (Stefansson et al. 2002). Gu and colleagues (2005)
reported that NMDA receptor currents and channel activity were significantly
decreased in the PFC after perfusion of NRG1, suggesting that elevated NRG1
signalling compromises NMDA function (Gu et al. 2005). Additionally, decreased
NR2C expression was found in individuals with schizophrenia that had an NRG1
polymorphism, suggesting deficits in NMDA receptor function (Schmitt et al. 2010).
Hahn et al. (2006) have found that increased NRG1–ErbB4 signalling (enhanced
association of ErbB4 receptors with both PSD-95 and the NR1 subunits) was
associated with suppressed NMDA receptor activation (reduced phosphorylation of
NR2A subunits) in schizophrenia (Fig. 1) (Hahn et al. 2006). It has also been reported
that the activation of Src kinases enhances NMDA receptor channel activity and
mediates the phosphorylation of NMDA subunits (Yu et al. 1997). This Src-mediated
enhancement of synaptic NMDA function could be suppressed by NRG1–ErbB4
signalling through PSD-95, causing hypofunction of NMDA receptors in pyramidal
neurons in the PFC and hippocampus under a preparation of blocked GABA
neurotransmission; and NRG1–ErbB4 signalling prevents the theta burst-induced
phosphorylation of NR2B by inhibiting Src kinase activity (Pitcher et al. 2011). On
the other hand, through activation of Fyn and Pyk2 kinases, NRG1–ErbB4 signalling
can stimulate phosphorylation of the NR2B subunit of the NMDA receptors
(Bjarnadottir et al. 2007).
3.2.3 Interaction
between
NRG1ErbB4
signalling
and
GABAergic
neurotransmission
Accumulated evidence supports the contribution of abnormal GABAergic
neurotransmission in the pathophysiology of schizophrenia (Benes 2009; Deng and
Huang 2006; Lewis and Gonzalez-Burgos 2006). NRG1–ErbB4 signalling plays a
critical role in GABAergic interneuron plasticity and transmission. For example, Chen
et al. (2010a) found that NRG1 increased GABAA receptor-mediated synaptic
currents in CA1 pyramidal cells. NRG1 also increases evoked release of GABA in the
PFC by directly activating ErbB4 receptors on presynaptic terminals (Woo et al.
2007). Moreover, impaired NRG1–ErbB4 signalling may induce a reduction of
GABA release, resulting in abnormal synchronisation of pyramidal cells, which is
related to deficits in working memory in schizophrenia (Lewis and Moghaddam 2006).
Another study found that NRG1 increases the function of GABAergic interneurons in
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vitro by promoting the frequency and amplitude of miniature excitatory postsynaptic
currents (mEPSCs), which supports the in vivo finding that mice with deletion of
ErbB4 receptors in parvalbumin-positive interneurons displayed reduced frequency
and amplitude of mEPSCs in interneurones (Ting et al. 2011).
3.3
A key role for NRG1ErbB4 signalling in integrating dopamine, GABA
and glutamate neurotransmission in relation to the pathophysiology of
schizophrenia
Given that dopamine, GABA and glutamate systems are responsible for the
pathophysiology of schizophrenia and are regulated by NRG1–ErbB4 signalling, a
key question is whether NRG1–ErbB4 signalling plays a crucial role in integrating
these systems? Also, how does this integrative role contribute to the pathophysiology
of schizophrenia? A critical step towards addressing these questions is to identify the
precise locations of ErbB4 receptors. A role for NRG1– ErbB4 signalling in
glutamatergic transmission between pyramidal cells in the cortex and hippocampus
was previously assumed (Barros et al. 2009; Bjarnadottir et al. 2007; Kwon et al.
2005; Mei and Xiong 2008). However, these reports were based on the discovery of
ErbB4 expression in pyramidal neurons in the cortex using in situ hybridisation and
immunohistological methods with low-specificity antibodies (Bernstein et al. 2006;
Thompson et al. 2007), as well as an association between ErbB4 and PSD-95 (Garcia
et al. 2000; Huang et al. 2000). A study using whole-cell recording in slice
preparations found that NRG1β suppresses Src-mediated EPSP in the pyramidal
neurons of mouse hippocampus and prefrontal cortex with blocked GABA
neurotransmission, and this effect was not observed in ErbB4 mutant mice
(Erbb4−/−HER4heart). This suggested that ErbB4 receptors are required for
suppression of Src-mediated EPSP in the pyramidal neurons by NRG1β in this
experiment (Pitcher et al. 2011). However, other studies using single cell analysis of
electrophysiologically characterised neurons combined with high-specificity
antibodies have provided evidence of a lack of ErbB4 expression in any pyramidal
cells in the cortex and hippocampus (Fazzari et al. 2010; Neddens and Buonanno
2010; Neddens et al. 2011). Instead, ErbB4 receptors are expressed predominately on
the GABA interneurons in the frontal cortex (Neddens et al. 2011), primarily (>98%
in the cortex) on the PV-positive interneurons, including basket and chandelier cells
that innervate the somata and the axon initial segment of pyramidal cells, respectively
(Fig. 1). Small numbers of ErbB4 receptors are expressed on calbindin-positive
interneurons that innervate the dendritic region of pyramidal cells (Fazzari et al. 2010;
Neddens et al. 2011). According to Neddens et al. (2011), ErbB4 receptors were not
detected at the presynapses in any GABA interneurons but are highly expressed
postsynaptically at glutamatergic synapses, where it binds to PSD-95 in GABAergic
interneurons (Fig. 1). These postsynaptic ErbB4 receptors regulate the formation
and/or maintenance of excitatory synapses onto GABAergic interneurons and
neuronal network activity (Cooper and Koleske 2011; Fazzari et al. 2010; Neddens et
al. 2011). In fact, recent studies have clearly shown that NRG1 regulates pyramidal
neuron activity and long-term potentiation (LTP) completely via ErbB4 in PVpositive interneurons in the frontal cortex and hippocampus (Chen et al. 2010a; Wen
et al. 2010). It is worthy of note that ErbB4 expression is significantly higher in the
ventral than the dorsal hippocampus of mice (Neddens and Buonanno 2010).
Consistently, NGR1 type III hypomorphic mice display disrupted activity in ventral
hippocampal-accumbens transmission (Nason et al. 2011), and subchronic peripheral
NRG1 treatment selectively increases neurogenesis in the ventral hippocampus
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(Mahar et al. 2011). In consideration of the fact that neonatal ventral hippocampus
lesions are a well-recognised model of schizophrenia (Lipska et al. 2003; Tseng et al.
2009), NRG1–ErbB4 signalling may interact with pyramidal cells and GABA
interneurons predominately through the ventral hippocampus. Furthermore, the
predominant location of ErbB4 receptors on PV-positive GABA interneurons in the
cortex and hippocampus is conserved across species from rodents to primates
including humans, which supports the relevance of rodents as an appropriate model to
study the mechanisms of NRG1–ErbB4 signalling in the pathophysiology of
schizophrenia (Cooper and Koleske 2011; Neddens et al. 2011).
NRG1 elicits a prolonged release of dopamine in the adult hippocampus, which in
turn suppresses or reverses LTP at hippocampal glutamatergic synapses (Kwon et al.
2008). Conversely, blockade of ErbB receptors produces a small but significant
decrease in dopamine release in the dorsal hippocampus of rats (Neddens et al. 2009).
Therefore, NRG1 may regulate hippocampal dopamine release by acting at ErbB4
receptors on dopamine terminals. However, since ErbB4 receptors are primarily
expressed on GABAergic interneurons in the hippocampus (as discussed above), it is
likely that NRG1-induced dopamine release may be through the action of GABAergic
interneurons (Balu and Coyle 2011; Kwon et al. 2008). Since both the cortex and
hippocampus are innervated by dopaminergic fibres from the ventral tegmental area
(VTA), an alternative mechanism is that NRG1 may regulate dopamine release in the
cortex and hippocampus by modulating VTA dopamine neurons. In fact, ErbB4
receptors are located in VTA and SN dopamine neurons of monkeys and humans
(Thompson et al. 2007; Zheng et al. 2009). A recent study in rats reported that 66–78%
of cells expressing mRNA for ErbB4 are positive for TH in the VTA and SN pars
lateralis, and an even higher (94–96%) number of neurons in the SN pars compacta
coexpress ErbB4 mRNA and TH (Abe et al. 2009). However, ErbB4 mRNA
reportedly does not colocalise with PV immunoreactivity in both the VTA and SN
(Abe et al. 2009). These results suggest that NRG1–ErbB4 signalling in the midbrain
may regulate the activity of excitatory glutamatergic synapses onto dopaminergic
neurons directly, but not through PV-positive interneurones (Fig. 1). Further studies
are required to examine whether NRG1–ErbB4 signalling regulates midbrain
dopamine neurons through other types of GABA interneurons, and whether it
regulates midbrain dopamine neurons through other brain regions.
The evidence discussed above supports the integral role for NRG1–ErbB4 signalling
in glutamatergic, GABAergic and dopaminergic neurotransmission; the question is
how this signalling pathway contributes to the pathophysiology of schizophrenia?
Recently, NRG1–ErbB4 signalling was reported to suppress Src-mediated increase of
synaptic NMDA transmission (Pitcher et al. 2011). In view of the fact that NRG1–
ErbB4 signalling is altered in the brain of schizophrenic patients (Bertram et al. 2007;
Chong et al. 2008; Hahn et al. 2006; Hashimoto et al. 2004; Law et al. 2006; Pan et al.
2011), the altered NRG1–ErbB4 signalling may induce functional changes of the
NMDA receptor via the Src pathway. In the case of elevated NRG1–ErbB4 signalling,
as shown in many post-mortem brain studies (reviewed above), it may induce NMDA
receptor hypofunction via the Src pathway, which may act directly on pyramidal
neurons or indirectly through GABAergic interneurons (Fig. 1) (Hahn 2011; Pitcher et
al. 2011). However, it should also be noted that some studies reported a decreased
expression of NRG1 (Bertram et al. 2007; Hashimoto et al. 2004). As discussed above,
NRG1–ErbB4 signalling can activate Fyn and Pyk2 kinases leading to increased
10

NMDA NR2B phosphorylation (Bjarnadottir et al. 2007), whereas hypofunction of
NRG1–ErbB4 signalling will cause decreased activation of Fyn and Pyk2 kinases and
NMDA phosphorylation, resulting abnormal modulation of glutamatergic
neurotransmission. This may also partly contribute to the pathophysiology of
schizophrenia (Bjarnadottir et al. 2007). Therefore, both increased and decreased
NRG1–ErbB4 signalling may lead to NMDA hypofunction. As presented in Fig. 1,
NMDA hypofunction may lead to deficits in GABAergic transmission by downregulating GAD67 (67-kDa isoform of glutamic acid decarboxylase) and decreasing
GABA production, which in turn cause further decreased excitatory activity of
pyramidal cells in the frontal cortex and ventral hippocampus. In fact, GAD67 was
decreased in ErbB4 knockout mice (Neddens and Buonanno 2010). Both NMDA
hypofunction and decreased excitatory projections from the frontal
cortex/hippocampus may lead to deficits of dopaminergic transmission in the
midbrain, which may affect pyramidal activity. The interactions between NRG1–
ErbB4 signalling and neurotransmission pathways may not only contribute to the
pathophysiology of schizophrenia, but also provide potential targets for schizophrenia
medication (see below).

4. THE EFFECTS OF ANTIPSYCHOTIC TREATMENT ON NRG1
ERBB4 SIGNALLING
Individuals with schizophrenia that have different NRG1 genotypes respond
differently to typical antipsychotic drugs (Kampman et al. 2004). However, to date,
there has been no systematic investigation on the effects of antipsychotic treatment on
NRG1–ErbB4 signalling, even though several studies have reported antipsychotic
drugs affect protein levels and mRNA expression of NRG1 and the ErbB4 receptor in
both animals and humans. An in vivo study using haloperidol, clozapine and
risperidone for 4 weeks in rats reported that haloperidol increased the protein levels of
total NRG1 and ErbB4 receptors, while clozapine reduced the protein expression of
NRG1 in the PFC; however all three antipsychotic drugs increased NRG1 and ErbB4
protein expression in the hippocampus (Wang et al. 2008). On the other hand, 12week treatment with haloperidol significantly reduces NRG1-induced ErbB4
activation in the PFC of mice (Hahn et al. 2006). Additionally, protein expression of
NRG1 in the human fetal brain aggregates (in vitro) was increased following a 3week exposure to clozapine, but not after haloperidol treatment (Chana et al. 2009).
Furthermore, 2-week treatment with risperidone and quetiapine significantly increases
NRG1 mRNA expression in PBLs in first-onset schizophrenia patients (Zhang et al.
2008, 2011). However, NRG1 type I protein in monkey serum did not change after 8week treatment with haloperidol (Shibuya et al. 2010). Together, these studies show a
trend where short-term treatment with antipsychotics (up to 4 weeks) increases the
expression (mRNA or protein) of NRG1 and ErbB4 receptors, while prolonged
antipsychotic treatment may decrease their expression. However, different
experimental conditions (i.e., different antipsychotics and various types of tissue
tested) may explain the contrasting findings reported in these studies. Furthermore,
although all current antipsychotic drugs target dopamine D2 receptors, they do have
different pharmacological profiles. For example, although haloperidol, risperidone,
clozapine and quetiapine are D2 antagonists, haloperidol (Ki=2.6) and risperidone
(Ki=3.77) have much higher binding affinities to D2 receptors than clozapine
(Ki=210) and quetiapine (Ki=770) (Correll 2010). On the other hand, clozapine
displays high affinity to 5-HT2A (Ki=2.59) and 5-HT2C (Ki=4.8) receptors, while
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risperidone has a high affinity to 5-HT2A (Ki=0.15) and moderate affinity to 5-HT2C
(Ki=32), and quetiapine has a moderate affinity to 5-HT2A (Ki=31), but no affinity to
5-HT2C (Ki=3500) (Correll 2010). It has been suggested that antagonism of serotonin
5-HT2A, 2C receptors (which interact with dopamine D2 receptor antagonism), is a
mechanism to achieve clinical efficacy of atypical antipsychotic drugs (Mathews and
David 2007; Meltzer and Massey 2011). Therefore, the differential effects of various
antipsychotic drugs on NRG1–ErbB4 expression may partly be explained by their
distinct pharmacological profiles.
Antipsychotic drugs can not only affect NRG1–ErbB4 signalling, but are also able to
reverse abnormal behaviours in animal models of schizophrenia with impaired
NRG1– ErbB4 signalling. For example, clozapine is effective at reversing the
hyperactivity in TMN domain mutant mice (Stefansson et al. 2002), Ig-like domain
mutant mice (Dejaegere et al. 2008), BACE1-knockout mice (Savonenko et al. 2008)
and ErbB4-deficient animals (Barros et al. 2009). Clozapine is also effective at
normalising abnormal lateral inhibition in NRG1 Ig-like domain mutant mice (Rimer
et al. 2005). Furthermore, PPI deficits can be improved by both haloperidol and
clozapine in Aph1B/C-γ-secretase-disturbed mice (Dejaegere et al. 2008), and by
clozapine in BACE1-knockout mice (Savonenko et al. 2008) and ErbB4-deficient
mice (Barros et al. 2009). A recent study has reported that PPI deficits caused by
neonatal treatment of NRG1 could be ameliorated by chronic treatment of risperidone
(Kato et al. 2011). Although the mechanism underlying antipsychotic corrections of
these behavioural deficits is not clear, it is likely to be via modulation of the
interactions between NRG1–ErbB4 pathways and neurotransmission pathways. For
example, several studies have shown that phosphorylation of the NR2B subunit was
inhibited in mice with TMN domain NRG1+/− mutation and ErbB4+/− mutation, and
this defect could be reversed by clozapine treatment (Bjarnadottir et al. 2007;
Moghaddam 2003).

5. NRG1 AS A POTENTIAL THERAPEUTIC TREATMENT FOR
PSYCHOTIC SYMPTOMS
As described above, several mutations in NRG1–ErbB4 signalling genes are
associated with different clinically relevant phenotypes, such as prepulse inhibition,
startle habituation, working memory, frontal lobe activation, and alterations in other
cognitive functions (Greenwood et al. 2012; Hall et al. 2006; Konrad et al. 2009;
Munafo et al. 2006; Yokley et al. 2012). Therefore, there is potential for the use of
NRG1 as a novel treatment option for patients with psychotic symptoms. Two proofof-concept studies for NRG1 treatment have been published by two independent
laboratories, confirming that peripherally administered NRG1 can pass the blood–
brain barrier, most likely via a receptor-mediated transport mechanism (Kastin et al.
2004; Rösler et al. 2011). The rapid uptake of peripheral NRG1 enables time-sensitive
treatment schedules, making NRG1 available both for acute and long-term treatment
schemes, as shown by neuroprotective effects following intravascular administration
in acute stroke models (Xu et al. 2004, 2006).
Animal studies have highlighted the time-sensitive effect of NRG1 administration on
neurodevelopment and behaviours. The long-lasting effects of postnatal NRG1
treatment have been assessed by Kato et al. (2011), who peripherally administered
NRG1 to newborn mice from postnatal days (PND) 2–10, which triggered an
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immediate increase in dopamine content and TH phosphorylation in the frontal cortex,
and a similar increase in the striatum at PND 11, with no changes in glutamatergic or
GABAergic neurotransmitter system proteins (Kato et al. 2011). The increase in
NRG1 activity during the corticolimbic fibre growing period resulted in long-lasting
effects beyond adolescence. The dopaminergic system remained altered with
increased dopamine metabolite levels in the adult frontal cortex and increased
dopamine release in this area (Kato et al. 2011). NRG1-treated mice displayed
reduced social interaction in adulthood as well as a lack of latent inhibition and
impaired PPI (Kato et al. 2011).
In contrast to the harmful consequences of NRG1 exposure during the developmental
period, three recent studies observed a potentially beneficial effect of NRG1
administration during adulthood. Adult mice receiving subcutaneous NRG1 for 3 days
showed increased cell proliferation and neurogenesis in the hippocampal dentate
gyrus as well as improved performance in the forced swim test (Mahar et al. 2011).
The antidepressant-like effect of NRG1 treatment appears to be the consequence of an
increase in neurogenesis, with the behavioural differences only visible 4 weeks after
treatment cessation and not acutely after administration (Mahar et al. 2011). Recent
work on a mouse model for Parkinson’s disease provides further evidence for
potentially beneficial neurotrophic effects of peripheral NRG1 administration
(Carlsson et al. 2011). Modelling the reduction of mesencephalic dopaminergic
neurons in patients with Parkinson’s disease, Carlsson and colleagues injected NRG1
intraperitoneally (i.p.) to adult mice for 8 days immediately after a neurotoxin 6OHDA injection into the striatum (Carlsson et al. 2011). Instant treatment onset (6 h
after 6-OHDA) of NRG1 attenuated the decrease of dopamine producing neurons in
the SN as well as lesion-related behavioural changes (Carlsson et al. 2011). Although
no clinical trial has been conducted to test the potential of NRG1 as a treatment option
for psychosis in humans, two recent successful phase II chronic trials using NRG1 to
treat heart failure strongly support the safety and tolerability of NRG1 treatment in a
clinical setting (Gao et al. 2010; Jabbour et al. 2011).

6. POTENTIAL TARGETS IN NRG1ERBB4 SIGNALLING AND
RELATED
PATHWAYS
FOR
NEXT
GENERATION
OF
ANTIPSYCHOTIC DRUGS
As discussed, significant progress has been achieved over the past several years
towards revealing the mechanistic roles of NRG1–ErbB4 signalling in the
pathophysiology of schizophrenia. These findings have identified potential targets that
provide insights for the development of a new generation of antipsychotic drugs.
Firstly, the recent finding that peripheral NRG1 treatment displayed antidepressantlike effects in adult animals (Mahar et al. 2011) suggests a potential to develop
molecules/ligands that bind to and modulate ErbB receptors. However, this approach
should be taken with caution due to the inverted U-shaped relationship between
ErbB4 activity and the expression of schizophrenia endophenotypes (Hahn 2011; Role
and Talmage 2007; Wen et al. 2010), as well as different effects of NRG1 treatment
in developing and adult animals (Kato et al. 2011; Mahar et al. 2011). Secondly, it is
possible to examine more specific targets within the downstream pathways of NRG1–
ErbB4 signalling. The recent finding, that NRG1–ErbB4 signalling inhibits Srcmediated enhancement of synaptic NMDA function, provides novel targets in the
frontal cortex and hippocampus for new antipsychotic drugs (Pitcher et al. 2011),
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since the majority of studies have showed that schizophrenia patients have increased
NRG1– ErbB4 signalling (Hahn 2011). Therefore, a drug aimed at specifically
restoring Src activity in schizophrenia could potentially be a new approach for
schizophrenia therapy (Fig. 1) (Hahn 2011; Pitcher et al. 2011). On the other hand, it
should be noted that some studies reported decreased expression of NRG1 (as
reviewed above); if this is the case, this may lead to different therapeutic approaches
in schizophrenia patients with decreased NRG1–ErbB4 signalling by activating Fyn
and Pyk2 kinases (Bjarnadottir et al. 2007). Thirdly, the finding that ErbB4 receptors
are located on PV-positive GABA interneurons in the frontal cortex and hippocampus,
a trait conserved between species from rodents to humans, provides another specific
approach for the development of antipsychotics by enhancing the function of PVpositive GABA interneurons. For example, PV-positive interneurons present a 5-fold
higher NR2A/NR2B ratio than pyramidal neurons, and these NR2A-containing
NMDA receptors regulate the expression of GAD67 in PV-positive GABA
interneurons (Kinney et al. 2006). The density of a subset of GABA interneurons with
co-expression of GAD67 and NR2A is decreased in the prefrontal and anterior
cingulated cortex of schizophrenic patients (Woo et al. 2004, 2008). Therefore, a drug
that selectively activates NR2A-containing NMDA receptors in PV-positive
interneurons could have therapeutic value to reverse the NMDA hypofunction
observed in patients with schizophrenia (Lewis and Gonzalez-Burgos 2006; Rico and
Marin 2011). In addition, a drug to modulate interactions between NRG1–ErbB4
signalling and the dopamine pathway may also be a valuable approach to
schizophrenia therapy.
Furthermore, the interactive points between NRG1 and other schizophrenia
susceptibility factors/pathways should not be excluded as possible future drug targets,
as research over the last decade has clearly shown that no single risk factor or related
pathway for schizophrenia can cause the disease, instead cumulative or synergistic
pathological effects seem likely (Balu and Coyle 2011; Karam et al. 2010). One
example is the interaction between ErbB4 and DISC1, due to their co-localisation in
the PSD of glutamate synapses and possible functional convergence (Hashimoto et al.
2007; Jaaro-Peled et al. 2009). Targeting both the NRG1–ErbB4 and DISC1–GSK3–
Akt pathways may provide specific targets for new antipsychotic drugs (Jaaro-Peled
et al. 2009; Ross and Margolis 2009). In addition, other schizophrenia susceptibility
factors, such as dysbindin-1, neuronal nitric oxide synthase (nNOS), carboxylterminal PDZ ligand of neuronal nitric oxide synthase (CAPON), and growth factor
receptor bound protein (Grb2), are also located in the PSD where signals from
neurotransmitters converge, making PSD itself a promising drug discovery target
(Hashimoto et al. 2007; Jaaro-Peled et al. 2009). In conclusion, identification of these
targets in NRG1–ErbB4 signalling and interacting pathways will provide unique
opportunities for the development of new generation antipsychotics with specific
efficacy and fewer side effects.
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Figure legends
Figure 1. A schematic diagram showing the hypothetical interaction between NRG1ErbB4 signalling and neurotransmission systems in schizophrenia. The output of
pyramidal neurons in the prefrontal cortex and ventral hippocampus is regulated by
excitatory glutamatergic neurons (orange colour) and inhibitory GABAergic
interneurons (shown in blue). Basket cells (BA) target the somata pyramidal neurons;
chandelier cells (CH) terminate at or near the axon hillock of pyramidal neurons.
Theses GABAergic interneurons are regulated by glutamatergic projections from
various brain regions, including the cortex, thalamus, hippocampus and amygdala.
Recent histological studies showed that ErbB4 receptors are located exclusively on
PV-positive GABAergic interneurons in the frontal cortex and hippocampus (Fazzari
et al 2010; Neddens and Buonanno 2010; Neddens et al 2011b), although an
electrophysiological study suggested a direct effect of NRG1 on the pyramidal
neurons (Pitcher et al 2011). NRG1 regulates NMDA receptors by activating ErbB4
that co-localise with postsynaptic density (PSD) 95, and then inhibits Src-mediated
enhancement of NMDA receptor function. In schizophrenia, in the case of increased
NRG1-ErbB4 signalling (as shown in many studies that are summarized in text), it
will cause NMDA receptor hypofunction by modulating Src activity, which may
directly act on pyramidal neurons or indirectly through GABAergic interneurons.
NMDA hypofunction may cause GABAergic deficits by down-regulating GAD67
(67-kilodalton isoform of glutamic acid decarboxylase) and decreasing GABA
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production. On the other hand, NRG1-ErbB4 signalling can activate Fyn and Pyk2
kinases leading to increased NMDA NR2B phosphorylation. Therefore, in the case of
hypofunctional NRG1-ErbB4 signalling, as observed in several studies in
schizophrenia patients, it may cause decreased activation of Fyn and Pyk2 kinases and
NMDA phosphorylation, also resulting NMDA hypofunction. In the midbrain, ErbB4
receptors are heavily expressed on dopaminergic neurons, whereas the function of
ErbB4 receptors in dopaminergic neurons in the midbrain is controversial.
Hypofunction of NMDA receptors may directly affect functioning of the
dopaminergic system (shown in green) in the midbrain, or indirectly via GABA
interneurons (unclear, shown as question mark), causing hyperfunction of dopamine
output to the striatum, and deficits of dopamine output to the cortex/hippocampus.
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